Inactive Instrument

Analyst Reco. Viracta Therapeutics, Inc. Nasdaq

Equities

RBC Cuts Price Target on Viracta Therapeutics to $6 From $7, Keeps Outperform, Speculative Risk	Nov. 10	MT
HC Wainwright Lowers Price Target on Viracta Therapeutics to $10 From $33, Maintains Buy Rating	23-07-05	MT
RBC Cuts Price Target on Viracta Therapeutics to $7 From $8, Maintains Outperform, Speculative Risk Rating	23-05-09	MT
Oppenheimer Adjusts Viracta Therapeutics Price Target to $16 From $14, Maintains Outperform Rating	23-03-27	MT
RBC Cuts Price Target on Viracta Therapeutics to $8 From $10, Maintains Outperform, Speculative Risk	22-11-11	MT
History shows stocks can weather rate hike cycle	22-03-16	RE
Viracta Therapeutics Initiated at Outperform by RBC With Speculative Risk Qualifier, Price Target Started at $10/Share	22-02-01	MT
Viracta Says Epstein-Barr Therapy Had 40% Overall Response Rate in Trial; Shares Fall	21-12-13	MT
VIRACTA THERAPEUTICS : HC Wainwright Starts Viracta Therapeutics at Buy With $35 Price Target	21-05-03	MT
VIRACTA THERAPEUTICS : SVB Leerink Initiates Viracta Therapeutics at Outperform With $18 Price Target	21-04-26	MT
VIRACTA THERAPEUTICS : Evercore ISI Starts Viracta Therapeutics at Outperform with $45 Price Target	21-03-25	MT

No results for this search